Keywords: ardea, rdea119, reduces, damage, uc, model, usa-based

Ardea's RDEA119 reduces damage in UC model

Article | 13 October 2008

Print This

USA-based Ardea Biosciences says data from a preclinical study of RDEA119, its lead mitogen-activated ERK kinase inhibitor, showed it to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in